Psoriasis Treatment Market by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α) Inhibitors, Interleukin 12 and 23 (IL-12/23) Inhibitors, Interleukin 17 (IL-17) Inhibitor, T cell Inhibitor]} - Forecast till 2027

Market Snapshot

As per the analysis by Market Research Future Reports (MRFR), the global psoriasis treatment market is anticipated to garner the market value of USD 13.1 billion, expanding at a CAGR of 7.3% during the assessment period from 2019 to 2025.

The psoriasis condition is estimated to be driven by environmental and genetic factors. The psoriasis treatment market 2020 is predicted to be majorly boosted by the rising awareness regarding the treatment, along with better healthcare infrastructure. Further, the adoption of a sedentary lifestyle, increased alcohol consumption, smoking, and an unhealthy diet are some of the other vital factors augmenting the global market. Further, the increased exposure to chemicals and pollutants has resulted in surging cases of psoriasis, prompting market growth.

On the contrary, the expensive costs associated are estimated to hamper the market growth during the review period. Nevertheless, the growing adoption of alternative psoriasis treatments and the prevailing competition among the key players is projected to enhance the psoriasis treatment market considerably.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2769 

Market Segmentation

The segment evaluation of the global psoriasis treatment market is done by treatment type and drug class.

The global market for psoriasis treatment, by drug class, is segmented into Interleukin-inhibitors, tumor necrosis factor inhibitors, and vitamin D analogs. Moreover, tumor necrosis factor inhibitors are segmented into infliximab, adalimumab, and etanercept. Furthermore, Interleukin-inhibitors is segmented into secukinumab, ustekinumab, ixekizumab, and brodalumab. Vitamin D analogs are segmented into calcipotriol, calcitriol, and tacalcitol.

The global market for psoriasis treatment, by treatment, is segmented into systemic, topicals, and biologics. Topicals are further segmented into topical non-steroid, over the counter (OTC) topicals, topical steroids. Systemic is segmented into cyclosporine, retinoid, and methotrexate. Biologics is sub-segmented into InterleU.K.in 12, and 23 (IL-12/23) inhibitors, tumour necrosis factor-alpha (TNF-a) inhibitors, InterleU.K.in 17 (IL-17) inhibitor, and T cell inhibitor.

Regional Analysis

Based on the region, the global psoriasis treatment market is segmented into the Americas, Asia-Pacific. Europe, and the Middle East and Africa.

As per the analysis, the global market is projected to be dominated by the Americas. The region is estimated to flourish owing to the increased awareness, rising patient pool, and the presence of established key players. According to a recent study, more than 8 million Americans are estimated to have been infected with psoriasis, with the US reporting 150,000 cases every year. In North America, the US and Canada are predicted to make the most significant contribution in boosting the regional market in the forthcoming period.

Europe is likely to obtain a second position by acquiring the second largest market share. The regional market is flourishing owing to the increased awareness about the ailment and the growing demand for an efficient treatment. Further, the rise in R&D activities to produce a long-term solution to the disease is likely to be another crucial factor in boosting the regional market.

On the contrary, the APAC region is estimated to be the fastest-growing market owing to the presence of a developing country and its focus on developing the healthcare infrastructure. Developing countries such as India, China, Japan are projected to drive the market at a fast pace by making a significant contribution to R&D.

The MEA region is anticipated to acquire the least market share during the review period owing to the presence of underdeveloped economies and lack of awareness.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769 

Key Players

The renowned players of the global psoriasis treatment market are UCB (Belgium), Novartis International AG (Switzerland), AstraZeneca (UK), Johnson & Johnson (US), Celgene Corporation (US), Pfizer Inc (US), AbbVie (US), Merck and Co. Inc (US), Amgen (US), and Eli Lilly and Company (US).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com